Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis Extends Bristol-Myers Partnership, Receives Milestone Payment for Validation

NEW YORK, Aug. 6-Exelixis and Bristol-Myers Squibb have agreed to prolong their target identification collaboration for an additional two years, Exelixis said today.


In their "mechanism of action" partnership, which began in 1999, Exelixis uses its comparative genetics and functional genomics capabilities to identify the targets of compounds supplied by the pharmaceutical company. That information is then used to improve the specificity and potency of potential drugs.


The partners did not reveal financial terms of the collaboration.


Exelixis also said today that it had received a "significant" milestone payment from Bristol-Myers Squibb based on the selection of a set of validated targets for cancer treatment, including genes involved in p53-mediated apoptosis.

The payment comes out of a collaboration struck in July 2001to develop drugs that destroy those cancers arising from defects in tumor suppressor gene pathways. Exelixis' role in this partnership is to identify and validate targets that trigger cancer cell death. In exchange, the company has an option to retain rights on some of these targets. Bristol-Myers made a $20 million equity investment and provides the company with a minimum of $3 million a year in licensing fees and research support.

Exelixis is a publicly held company based in South San Francisco, Calif.

For additional information about its partnerships with Bristol-Myers, see the press releases.


The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more